Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851–861. https://doi.org/10.1016/S2468-1253(22)00165-0

Article  PubMed  Google Scholar 

Zhou F, Zhou J, Wang W et al (2019) Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatol 70:1119–1133. https://doi.org/10.1002/hep.30702

Article  Google Scholar 

Dai W, Ye L, Liu A et al (2017) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Med (Baltimore) 96:e8179. https://doi.org/10.1097/MD.0000000000008179

Article  Google Scholar 

Morrison AE, Zaccardi F, Khunti K et al (2019) Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis. Liver Int 39:557–567. https://doi.org/10.1111/liv.13994

Article  CAS  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterol 158:1999–2014. https://doi.org/10.1053/j.gastro.2019.11.312

Article  CAS  Google Scholar 

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V et al (2018) Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterol 155:443–457. https://doi.org/10.1053/j.gastro.2018.04.034

Article  Google Scholar 

Taylor RS, Taylor RJ, Bayliss S et al (2020) Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol 158:1611–1625. https://doi.org/10.1053/j.gastro.2020.01.043

Article  CAS  Google Scholar 

Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterol 158:1851–1864. https://doi.org/10.1053/j.gastro.2020.01.052

Article  CAS  Google Scholar 

Cusi K, Isaacs S, Barb D et al (2022) American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28:528–562. https://doi.org/10.1016/j.eprac.2022.03.010

Article  PubMed  Google Scholar 

Procino F, Misciagna G, Veronese N et al (2019) Reducing NAFLD-screening time: a comparative study of eight diagnostic methods offering an alternative to ultrasound scans. Liver Int 39:187–196. https://doi.org/10.1111/liv.13970

Article  PubMed  Google Scholar 

Koehler EM, Plompen EP, Schouten JN et al (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatol 63:138–147. https://doi.org/10.1002/hep.27981

Article  CAS  Google Scholar 

Wang S, Hu M, Qian Y et al (2020) CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomed Pharmacother 131:110680. https://doi.org/10.1016/j.biopha.2020.110680

Article  CAS  PubMed  Google Scholar 

Berres ML, Papen S, Pauels K et al (2009) A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 50:370–376. https://doi.org/10.1016/j.jhep.2008.09.016

Article  CAS  PubMed  Google Scholar 

Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209

CAS  PubMed  Google Scholar 

Jin X, Fu B, Wu ZJ et al (2020) Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Hepatobiliary Pancreat Dis Int 19:384–389. https://doi.org/10.1016/j.hbpd.2020.05.009

Article  CAS  PubMed  Google Scholar 

Li H, Yan T, Zhu Z et al (2018) Diagnostic value of serum chitinase 3-like protein 1 in chronic liver disease with significant fibrosis and cirrhosis. Chin J Hepatol 26:337–341

CAS  Google Scholar 

Kumagai E, Mano Y, Yoshio S et al (2016) Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 6:35282. https://doi.org/10.1038/srep35282

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee CK, Perez-Atayde AR, Mitchell PD et al (2013) Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children’s hospital experience. J Pediatr 163:1058–1064. https://doi.org/10.1016/j.jpeds.2013.04.044

Article  CAS  Google Scholar 

Huang H, Wu T, Mao J et al (2015) CHI3L1 is a liver-enriched, noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis. OMICS 19:339–345. https://doi.org/10.1089/omi.2015.0037

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim AD, Kui L, Kaufmann B et al (2023) Myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression. J Mol Med (Berl) 101:813–828. https://doi.org/10.1007/s00109-023-02325-4

Article  CAS  PubMed  Google Scholar 

Zhou YJ, Ye FZ, Li YY et al (2019) Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. United Eur Gastroenterol J 7:1124–1134. https://doi.org/10.1177/2050640619868352

Article  CAS  Google Scholar 

Luo W, Zhang L, Sheng L et al (2021) Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 13:6. https://doi.org/10.1186/s13098-021-00624-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nielsen AR, Erikstrup C, Johansen JS et al (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57:3078–3082. https://doi.org/10.2337/db08-0182

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatol 65:1557–1565. https://doi.org/10.1002/hep.29085

Article  CAS  Google Scholar 

Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol 67:328–357. https://doi.org/10.1002/hep.29367

Article  Google Scholar 

Xiao G, Zhu S, Xiao X et al (2017) Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatol 66:1486–1501. https://doi.org/10.1002/hep.29302

Article  CAS  Google Scholar 

Harrison SA, Ratziu V, Boursier J et al (2020) A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 5:970–985. https://doi.org/10.1016/S2468-1253(20)30252-1

Article  PubMed  Google Scholar 

Higashiyama M, Tomita K, Sugihara N et al (2019) Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis. Hepatol Res 49:1316–1328. https://doi.org/10.1111/hepr.13396

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishimura N, De Battista D, McGivern DR et al (2021) Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci USA 118:e2019633118. https://doi.org/10.1073/pnas.2019633118

Article  PubMed  PubMed Central  Google Scholar 

Kyrgios I, Galli-Tsinopoulou A, Stylianou C et al (2012) Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metab 61:562–568. https://doi.org/10.1016/j.metabol.2011.09.004

Article  CAS  Google Scholar 

Catalan V, Gomez-Ambrosi J, Rodriguez A et al (2011) Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab 96:200–209. https://doi.org/10.1210/jc.2010-0994

Article  CAS  PubMed  Google Scholar 

Zhang S, Sousa A, Lin M et al (2021) Role of chitinase 3-like 1 protein in the pathogenesis of hepatic insulin resistance in nonalcoholic fatty liver disease. Cells 10:201. https://doi.org/10.3390/cells10020201

Article  PubMed  PubMed Central  Google Scholar 

Hashimoto E, Farrell GC (2009) Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis? J Gastroenterol Hepatol 24:501–503. https://doi.org/10.1111/j.1440-1746.2009.05806.x

Article  PubMed  Google Scholar 

Wong VW, Irles M, Wong GL et al (2019) Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 68:2057–2064. https://doi.org/10.1136/gutjnl-2018-317334

Article  CAS  PubMed  Google Scholar